Latest On Co-Diagnostics, Inc (CODX):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 07:50 EST | News | Co-Diagnostics, Inc. (CODX) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-11 18:15 EST | News | Co-Diagnostics GAAP EPS of -$0.20 beats by $0.03, revenue of $0.61M misses by $0.49M | N/A | |
| 2023-05-11 03:27 EST | News | Co-Diagnostics Q1 2023 Earnings Preview | N/A | |
| 2023-03-21 03:13 EST | News | Co-Diagnostics hits 52-week low as H.C. Wainwright cuts rating | N/A | |
| 2023-03-17 07:15 EST | News | Co-Diagnostics, Inc. (CODX) Q4 2022 Earnings Call Transcript | N/A | |
About Co-Diagnostics, Inc (CODX):
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
General
- Name Co-Diagnostics, Inc
- Symbol CODX
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDiagnostics & Research
- Full Time Employees 39
- Fiscal Year EndDecember
- IPO Date2017-07-12
- Gic SectorHealth Care
- Gic GroupHealth Care Equipment & Services
- Gic IndustryHealth Care Equipment & Supplies
- Gic SubIndustryHealth Care Equipment
- Web URLhttp://www.codiagnostics.com
Valuation
- Trailing PE 12.2
- Forward PE 7.69
- Price/Sales (Trailing 12 Mt.) 7.2
- Price/Book (Most Recent Quarter) 7.37
- Enterprise Value Revenue 7.61
- Enterprise Value EBITDA 14.4
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate $0.68
- Profit Margin 59%
- Operating Margin 51%
- Return on Assets 51%
- Return on Equity 100%
- Revenue 47.52 million
- Earnings Per Share $1.12
- Revenue Per Share $2
- Gross Profit 102543
- Quarterly Earnings Growth 52559.1%
Highlights
- Market Capitalization 387.01 million
- EBITDA 24.14 million
- PE Ratio -1.18
- Analyst Target Price $27
- Book Value Per Share $1.87
Share Statistics
- Shares Outstanding 28.27 million
- Shares Float 26.42 million
- % Held by Insiders 652%
- % Held by Institutions 33.01%
- Shares Short 3.95 million
- Shares Short Prior Month 4.99 million
- Short Ratio 1.99
- Short % of Float 14%
- Short % of Shares Outstanding 14%
Technicals
- Beta -1.82
- 52 Week High $29.99
- 52 Week Low $6.81
- 50 Day Moving Average 14.87
- 200 Day Moving Average 12.87
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Co-Diagnostics, Inc (CODX) Dividend Calendar:
Co-Diagnostics, Inc (CODX) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Co-Diagnostics, Inc (CODX) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Co-Diagnostics, Inc (CODX) Chart:
Co-Diagnostics, Inc (CODX) News:
Below you will find a list of latest news for Co-Diagnostics, Inc (CODX) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Co-Diagnostics, Inc (CODX) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CODX Trades:
Co-Diagnostics, Inc (CODX) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | EFFECT (Notice of Effectiveness) | |
| 2020-11-03 | 10-Q/A (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-03 | DEF 14A (Other definitive proxy statements) | |
| 2020-11-03 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-11-02 | 8-K (Current report) | |
| 2020-10-23 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-08-13 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-06-08 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-06-08 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-04 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-06-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-04 | 5 (Annual statement of changes in beneficial ownership of securities) | |
| 2020-05-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-15 | 8-K (Current report) | |
| 2020-05-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
Co-Diagnostics, Inc (CODX) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Co-Diagnostics, Inc (CODX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 652%
Institutional Ownership: 3301%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-05-28 | RICHARD S SERBIN | Director | Sell | 7,500.00 | 18.00 | 135,000.00 | 0.00 | |
| 2020-05-28 | RICHARD S SERBIN | Director | Sell | 17,500.00 | 18.03 | 315,525.00 | 0.00 | |
| 2020-05-28 | RICHARD S SERBIN | Director | Buy | 25,000.00 | 3.96 | 99,000.00 | 25,000.00 | |
| 2020-05-26 | Eugene Durenard | Director | Sell | 25,000.00 | 18.26 | 456,500.00 | 0.00 | |
| 2020-05-20 | Eugene Durenard | Director | Sell | 25,000.00 | 18.40 | 460,000.00 | 0.00 | |
| 2020-05-20 | Eugene Durenard | Director | Buy | 25,000.00 | 0.71 | 17,750.00 | 25,000.00 | |
| 2020-05-20 | Eugene Durenard | Director | Buy | 25,000.00 | 3.96 | 99,000.00 | 25,000.00 | |
| 2020-05-19 | RICHARD S SERBIN | Director | Sell | 25,000.00 | 18.50 | 462,500.00 | 0.00 | |
| 2020-05-19 | RICHARD S SERBIN | Director | Buy | 25,000.00 | 0.71 | 17,750.00 | 25,000.00 | |
| 2018-12-06 | America 2030 Capital, LLC | 10% Share Holder | Sell | 1,134,898.00 | 0.01 | 11,348.98 | 0.00 | |
| 2018-07-18 | America 2030 Capital, LLC | 10% Share Holder | Sell | 1,134,897.00 | 0.01 | 11,348.97 | 1,134,898.00 | |
| 2018-05-11 | Brent Satterfield | Chief Science Officer | Buy | 1,305.00 | 1.82 | 2,375.10 | 2,275,000.00 | |
| 2018-05-03 | Brent Satterfield | Chief Science Officer | Buy | 500.00 | 1.91 | 955.00 | 2,273,695.00 | |
| 2018-04-23 | Brent Satterfield | Chief Science Officer | Buy | 500.00 | 2.02 | 1,010.00 | 2,273,198.00 | |
| 2018-04-16 | Brent Satterfield | Chief Science Officer | Buy | 500.00 | 1.94 | 970.00 | 2,272,698.00 | |
| 2018-04-09 | Brent Satterfield | Chief Science Officer | Buy | 2,400.00 | 4,920.00 | 11,808,000.00 | 2,272,198.00 | |
| 2017-12-13-07:00 | REED L BENSON | CFO and Secretary | Sell | 17,792.00 | 4.65 | 82,732.80 | 0.00 | |
| 2017-12-13-07:00 | REED L BENSON | CFO and Secretary | Sell | 2,776.00 | 4.65 | 12,908.40 | 17,792.00 | |